Loncastuximab Tesirine
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.
Journal: Seminars in hematology
Published: September 17, 2025
Deep Learning-Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial.
Journal: JCO clinical cancer informatics
Published: July 16, 2025
Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system.
Journal: PloS one
Published: July 02, 2025
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.
Journal: Leukemia & lymphoma
Published: June 30, 2025
Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.
Journal: Cancers
Published: June 29, 2025
Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.
Journal: Cancers
Published: June 26, 2025
Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.
Journal: British journal of haematology
Published: June 17, 2025
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary.
Journal: Future oncology (London, England)
Published: May 30, 2025
How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study.
Journal: Future oncology (London, England)
Published: May 29, 2025
Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.
Journal: Chembiochem : a European journal of chemical biology
Published: April 11, 2025
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Journal: Journal of medical economics
Published: March 31, 2025
Last Updated: 02/24/2026